Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Age-Related Macular Degeneration Linked to Severe Vascular Disease

Caitlin E. Cox

November 18, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Daily News

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

Shelley Wood

August 23, 2022

News Daily News

CV Risk Factors, Disease Projected to Explode in Coming Decades

L.A. McKeown

August 01, 2022

News Daily News

‘Code Blue’ for the Dire CVD Health Status of Most US Adults

Michael O'Riordan

July 05, 2022

News Daily News

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Michael O'Riordan

June 17, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Yael L. Maxwell

February 22, 2022

News Daily News

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Yael L. Maxwell

February 17, 2022

Advertisement

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Age-Related Macular Degeneration Linked to Severe Vascular Disease

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill

CV Risk Factors, Disease Projected to Explode in Coming Decades

‘Code Blue’ for the Dire CVD Health Status of Most US Adults

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Icosapent Ethyl Cost-effective Compared With Standard Care: REDUCE-IT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content